Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations

Journal of the Neurological Sciences

Volumn 319, Issue 1-2, 2012, Pages 18-23

  Praksova, Petra ^a   Stourac, Pavel ^a,b   Bednarik, Josef ^a,b   Vlckova, Eva ^a,b   Mikulkova, Zuzana ^b   Michalek, Jaroslav ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Central memory T cells; Glatiramer acetate; Interferon beta; Multiple sclerosis; Naive T cells; Regulatory T cells

Indexed keywords

BETA INTERFERON; GLATIRAMER;

ADOLESCENT; ADULT; ARTICLE; CD4 LYMPHOCYTE PERCENTAGE; CELL POPULATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HELPER CELL; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ADOLESCENT; ADULT; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 84862764046     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2012.05.036     Document Type: Article

References (36)

1. Nikić I, Merkler D, Sorbara C, Brinkoetter M, Kreutzfeldt M, Bareyre FM, et al. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med 2011;17:495-9.
2. Hofstetter HH, Gold R, Hartung H-P. Th17 cells inMS and experimental autoimmune encephalomyelitis. Int MS J 2009;16:12-8.
3. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-17. (Pubitemid 30390191)
4. Neumann H, Medana IM, Bauer J, Lassmann H. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 2002;25:313-9. (Pubitemid 34667013)
5. Raine CS. Multiple sclerosis: immune system molecule expression in the central nervous system. J Neuropathol Exp Neurol 1994;53:328-37. (Pubitemid 24216030)
6. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401:708-12.
7. Afzali B, Lombardi G, Lechler RI, Lord GM. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007;148:32-46. (Pubitemid 46365005)
8. Fietta P, Delsante G. The effector T helper cell triade. Riv Biol 2009;102:61-74.
9. Haas J, Hug A, Viehöver A, Fritzsching B, Falk CS, Filser A, et al. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol 2005;35:3343-52. (Pubitemid 41672538)
10. Horwitz DA, Regulatory T. Cells in systemic lupus erythematosus: past, present and future. Arthritis Res Ther 2008;10:227.
11. Jadidi-Niaragh F, Mirshafiey A. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand J Immunol 2011;74:1-13.
12. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, GarrenH, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002;8:500-8. (Pubitemid 34546753)
13. Lee DH, Linker RA, Gold R. Spotlight on fumarates. Int MS J 2008;15:12-8.
14. Hartung HP, Bar-Or A, Zoukos Y. What do we know about the mechanism of action of disease-modifying treatments in MS? J Neurol 2004;251:12-29.
15. Ramgolam VS, Markovic-Plese S. Interferon-beta inhibits Th17 cell differentiation in patients with multiple sclerosis. Endocr Metab Immune Disord Drug Targets 2010;10:161-7.
16. Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 2002;58:3-9.
17. de Andrés C, Aristimuño C, de Las Heras V, Martínez-Ginés ML, Bartolomé M, Arroyo R, et al. Interferon beta-1a therapy enhances CD4+regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis. J Neuroimmunol 2007;182:204-11. (Pubitemid 46026708)
18. Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P, et al. Helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010;16:406-12.
19. Toker A, Slaney CY, Bäckström BT, Harper JL. Glatiramer acetate treatment directly targets CD11b(+)Ly6G(-) monocytes and enhances the suppression of autoreactive T cells in experimental autoimmune encephalomyelitis. Scand J Immunol 2011;74: 235-43.
20. Chitnis T. The role of CD4 T cells in the pathogenesis of multiple sclerosis. Int Rev Neurobiol 2007;79:43-72.
21. O'Brien K, Gran B, Rostami A. T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunotherapy 2010;2:99-115.
22. Okuda Y, Okuda M, Apatoff BR, Posnett DN. The activation of memory CD4(+) T cells and CD8(+) T cells in patients with multiple sclerosis. J Neurol Sci 2005;235: 11-7. (Pubitemid 41039087)
23. Crucian B, Dunne P, Friedman H, Ragsdale R, Pross S, Widen R. Alterations in levels of CD28-/CD8+ suppressor cell precursor and CD45RO+/CD4+ memory T lymphocytes in the peripheral blood of multiple sclerosis patients. Clin Diagn Lab Immunol 1995;2:249-52.
24. Hafler DA, Slavik JM, Anderson DE, O'Connor KC, De Jager P, Baecher-Allan C. Multiple sclerosis. Immunol Rev 2005;204:208-31. (Pubitemid 40460504)
25. Anderton SM. Treg and T-effector cells in autoimmune CNS inflammation: a delicate balance, easily disturbed. Eur J Immunol 2010;40:3321-4.
26. Feger U, Luther C, Poeschel S, Melms A, Tolosa E, Wiendl H. Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients. Clin Exp Immunol 2007;147:412-8. (Pubitemid 46208041)
27. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004;199:971-9. (Pubitemid 38481088)
28. Venken K, Hellings N, Thewissen M, Somers V, Hensen K, Rummens JL, et al. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology 2008;123:79-89. (Pubitemid 350255996)
29. Puissant-Lubrano B, Viala F, Winterton P, Abbal M, Clanet M, Blancher A. Thymic output and peripheral T lymphocyte subsets in relapsing-remitting multiple sclerosis patients treated or not by IFN-beta. J Neuroimmunol 2008;193:188-94.
30. Pentón-Rol G, Cervantes-Llanos M, Cabrera-Gómez JA, Alonso-Ramírez R, Valenzuela-Silva C, Rodríguez-Lara R, et al. Treatment with type I interferons induces a regulatory T cell subset in peripheral blood mononuclear cells from multiple sclerosis patients. Int Immunopharmacol 2008;8:881-6.
31. Namdar A, Nikbin B, Ghabaee M, Bayati A, Izad M. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study. J Neuroimmunol 2010;218:120-4.
32. Lalive PH, Neuhaus O, Benkhoucha M, Burger D, Hohlfeld R, Zamvil SS, et al. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs 2011;25:401-14.
33. Putheti P, Soderstrom M, Link H, Huang Y-M. Effect of glatiramer acetate (Copaxone) on CD4+CD25high T regulatory cells and their IL-10 production in multiple sclerosis. J Neuroimmunol 2003;144:125-31. (Pubitemid 37329937)
34. Bequm-Haque S, Christy M, Ochoa-Reparaz J, Nowak EC, Mielcarz D, Haque A, et al. Augmentation of regulatory B cell activity in experimental allergic encephalomyelitis by glatiramer acetate. J Neuroimmunol 2011;232:136-44.
35. Vallittu AM, Saraste M, Airas L. CCR7 expression on peripheral blood lymphocytes is up-regulated following treatment of multiple sclerosis with interferon-beta. Neurol Res 2007;29:763-6. (Pubitemid 350255147)
36. Kivisäkk P,Mahad DJ, CallahanMK, Sikora K, Trebst C, Tucky B, et al. Expression of CCR7 in multiple sclerosis: implications for CNS immunity. Ann Neurol 2004;55:627-38. (Pubitemid 38544322)